PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Mahaffey, Kenneth W.
TI  - Results from the TRA•CER Trial
DP  - 2011  01
TA  - MD Conference Express
PG  - 13--14
VI  - 11
IP  - 15
4099  - http://mdc.sagepub.com/content/11/15/13.short
4100  - http://mdc.sagepub.com/content/11/15/13.full
AB  - The results of the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome [TRA•CER] trial showed that vorapaxar does not significantly improve outcomes in high-risk patients with non-ST-segment elevation acute coronary syndrome and significantly increases the risk of major bleeding, including intracranial hemorrhage.